The estimated Net Worth of James Anthony Cannon is at least $346 millier dollars as of 7 May 2019. James Cannon owns over 15,000 units of Alaunos Therapeutics Inc stock worth over $346,304 and over the last 18 years James sold ZIOP stock worth over $0.
James has made over 5 trades of the Alaunos Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently James exercised 15,000 units of ZIOP stock worth $10,500 on 7 May 2019.
The largest trade James's ever made was exercising 20,000 units of Alaunos Therapeutics Inc stock on 12 December 2017 worth over $54,600. On average, James trades about 3,200 units every 44 days since 2006. As of 7 May 2019 James still owns at least 398,050 units of Alaunos Therapeutics Inc stock.
You can see the complete history of James Cannon stock trades at the bottom of the page.
James's mailing address filed with the SEC is C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON, MA, 02129.
Over the last 18 years, insiders at Alaunos Therapeutics Inc have traded over $2,792,771 worth of Alaunos Therapeutics Inc stock and bought 7,941,160 units worth $39,823,909 . The most active insiders traders include Randal J Kirk, Randal Jintrexon Corp Kirk et Lindsay A Md Rosenwald. On average, Alaunos Therapeutics Inc executives and independent directors trade stock every 72 days with the average trade being worth of $152,086. The most recent stock trade was executed by Groot Eleanor De on 22 December 2021, trading 20,132 units of ZIOP stock currently worth $25,568.
Ziopharm Oncology is an immuno-oncology company focused on developing end-to-endcost-effective solutions using its non-viralSleeping Beauty platform for TCR and CAR T-cell therapies and immune-stimulating gene therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty platform genetically modifies T cells with DNA plasmids to express T-cell receptors (TCRs) to target specific antigens in solid tumors and chimeric antigen receptors (CARs) to target CD19 in blood cancers with the Company's 3rd generation T-cell manufacturing process, rapid personalized manufacture (RPM). The Sleeping Beauty platform is being advanced in collaboration with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and Eden BioCell. The Company also is developing its Controlled IL-12 platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in combination with immune checkpoint inhibitors to treat brain cancer, including in collaboration with Regeneron Pharmaceuticals.
Alaunos Therapeutics Inc executives and other stock owners filed with the SEC include: